Scpharmaceuticals Inc (NASDAQ:SCPH) has received an average broker rating score of 1.00 (Strong Buy) from the three brokers that provide coverage for the stock, Zacks Investment Research reports. Three analysts have rated the stock with a strong buy recommendation.
Brokers have set a 1 year consensus price objective of $12.67 for the company and are predicting that the company will post ($0.50) earnings per share for the current quarter, according to Zacks. Zacks has also given Scpharmaceuticals an industry rank of 95 out of 255 based on the ratings given to its competitors.
Several equities analysts have issued reports on SCPH shares. Zacks Investment Research upgraded Scpharmaceuticals from a “hold” rating to a “buy” rating and set a $5.25 price objective for the company in a research report on Friday, August 17th. Jefferies Financial Group cut their price objective on Scpharmaceuticals from $26.00 to $12.00 and set a “buy” rating for the company in a research report on Thursday, June 14th. Leerink Swann cut their price objective on Scpharmaceuticals from $20.00 to $12.00 and set an “outperform” rating for the company in a research report on Thursday, June 14th. Finally, BMO Capital Markets cut their price objective on Scpharmaceuticals from $24.00 to $14.00 and set an “outperform” rating for the company in a research report on Thursday, June 14th.
SCPH stock traded up $0.25 during trading on Tuesday, hitting $5.31. The company had a trading volume of 1,606 shares, compared to its average volume of 47,923. The company has a debt-to-equity ratio of 0.10, a current ratio of 13.80 and a quick ratio of 13.80. The firm has a market cap of $94.15 million and a price-to-earnings ratio of -0.66. Scpharmaceuticals has a fifty-two week low of $4.10 and a fifty-two week high of $18.17.
Scpharmaceuticals (NASDAQ:SCPH) last issued its quarterly earnings data on Tuesday, August 14th. The company reported ($0.53) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.57) by $0.04. research analysts anticipate that Scpharmaceuticals will post -2.09 earnings per share for the current year.
Institutional investors and hedge funds have recently modified their holdings of the business. Millennium Management LLC bought a new stake in shares of Scpharmaceuticals during the fourth quarter worth $462,000. Schwab Charles Investment Management Inc. bought a new stake in shares of Scpharmaceuticals during the first quarter worth $167,000. Northern Trust Corp bought a new stake in shares of Scpharmaceuticals during the first quarter worth $595,000. BlackRock Inc. increased its holdings in Scpharmaceuticals by 21,048.8% in the first quarter. BlackRock Inc. now owns 288,469 shares of the company’s stock valued at $3,577,000 after purchasing an additional 287,105 shares during the last quarter. Finally, Citigroup Inc. bought a new stake in Scpharmaceuticals in the first quarter valued at about $481,000. Hedge funds and other institutional investors own 43.59% of the company’s stock.
Scpharmaceuticals Company Profile
scPharmaceuticals Inc, a clinical-stage pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is Furoscix, a drug-device combination product that is under development for treatment of worsening or decompensated heart failure outside of the inpatient setting.
See Also: Earnings Per Share (EPS) Explained
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Scpharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scpharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.